PLoS ONE (Jan 2022)

The importance of body composition assessment for patients with advanced hepatocellular carcinoma by bioelectrical impedance analysis in lenvatinib treatment.

  • Kenji Yamaoka,
  • Kenichiro Kodama,
  • Tomokazu Kawaoka,
  • Masanari Kosaka,
  • Yusuke Johira,
  • Yuki Shirane,
  • Ryoichi Miura,
  • Shigeki Yano,
  • Serami Murakami,
  • Kei Amioka,
  • Kensuke Naruto,
  • Yuwa Ando,
  • Yumi Kosaka,
  • Shinsuke Uchikawa,
  • Takuro Uchida,
  • Hatsue Fujino,
  • Takashi Nakahara,
  • Eisuke Murakami,
  • Wataru Okamoto,
  • Masami Yamauchi,
  • Daiki Miki,
  • Michio Imamura,
  • Shoichi Takahashi,
  • Akiko Nagao,
  • Kazuaki Chayama,
  • Hiroshi Aikata

DOI
https://doi.org/10.1371/journal.pone.0262675
Journal volume & issue
Vol. 17, no. 1
p. e0262675

Abstract

Read online

Background and aimsThe aim of this study was to investigate the relationship between body composition before lenvatinib treatment and prognosis in patients with hepatocellular carcinoma (HCC). We also assessed the relationship between the rate of change in body composition after lenvatinib treatment and prognosis.MethodsEighty-one patients with advanced HCC who were treated with lenvatinib were enrolled. We assessed prognosis, various clinical data, body composition parameters obtained by bioelectrical impedance analysis (BIA), and handgrip strength.ResultsMultivariate analysis showed that an extracellular water to total body water ratio (ECW/TBW) ≤ 0.400 at treatment initiation was associated with longer overall survival (OS), progression-free survival (PFS), and post-progression survival (PPS) (OS: hazard ratio [H0R], 4.72; 95% CI, 12.03-11.00; P ConclusionBody composition assessment by BIA before and after lenvatinib treatment is useful in predicting prognosis in lenvatinib-treated patients with HCC.